Logo-Cardalis-usa
cardalis-us-2-left

Congestive Heart Failure
Just Got Easier To Treat.

HubSpot Video
acvim-recommendedActives recommended by ACVIM guidelines1.unique-combinationUnique combination chewable-for-dogsChewable tablets for dogs
In 2019, the American College of Veterinary Internal Medicine (ACVIM) updated their consensus guidelines for the diagnosis and treatment of mitral valve disease in dogs1. The new guidelines for treatment of CHF include spironolactone to help mitigate the effects of the renin-angiotensin-aldosterone system (RAAS). This standard has become known as Quad Therapy. The combination of Benazepril and Spironolactone in CARDALIS™ provides a unique combination of active ingredients to block the effects of the RAAS cascade. These active ingredients are recommended by the ACVIM to treat CHF at the onset of signs.

ACVIM Classification

cardali efficacyGreater efficacy compared to benazepril aloneComplete Blockage of the RAAS cascadeComplete blockage of the RAAS cascade2,3,4,5 Myxomatous Mitral Valve Disease MMVDMyxomatous Mitral Valve Disease (MMVD)

CHF is a devastating diagnosis for pet owners. Help your clients improve their compliance with once daily dosing. Help your patients, who may be struggling to take their medications, with a highly palatable chewable tablet. CARDALIS™ offers the opportunity to improve compliance AND your patient’s survival6.

Learn more about MMVD and treating with the AVCIM Guidelines.

e-learning-1RACE®-approved
Continued Education (CE)events-1Register for events email-iconSign up for our
newsletter to recieve
updates on cardiology

Contact Sales Representative

Contact Us
rep

References

    1. Keene et al. 2019. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 33(3):1127-1140. 
      https://doi.org/10.1111/jvim.15488
    2. Atkins CE, Häggström J. 2012. Pharmacologic Management of Myxomatous Mitral Valve Disease in Dogs. J Vet Cardiol. 14(1):165-184.
      https://doi.org/10.1016/j.jvc.2012.02.002
    3. Ovaert P, Elliott J, et al. 2010. Aldosterone receptor antagonists how cardiovascular actions may explain their beneficial effects in heart failure. J Vet Pharmacol Ther. 33(2):109-117.
      https://doi.org/10.1111/j.1365-2885.2009.01122.x
    4. Ames MK, Atkins CE. 2016. BEYOND FUROSEMIDE: THE ROLE OF DIURETICS IN CONGESTIVE HEART FAILURE Part 2: Spironolactone. Today’s Veterinary Practice. 6(3), 87-92.
      https://todaysveterinarypractice.com/the-role-of-diuretics-in-congestive-heart-failure-part-2-spironolactone/
    5. Ames MK, Atkins CE, Pitt B. 2019. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 33(2):363-382. Review. Erratum in: J Vet Intern Med.33(5):2551.
      https://dx.doi.org/10.1111%2Fjvim.15454
    6. Coffman, M, Guillot, E, Blondel, T, et al. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST). J Vet Intern Med. 2021; 1– 15. https://doi.org/10.1111/jvim.16155

CARDALIS and the CARDALIS logo trademarks are the property of Ceva Santé Animale S.A.

Important Safety Information

Do not administer in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs) in dogs with renal insufficiency. Do not use in dogs with hypoadrenocorticism (Addison’s disease), hyperkalemia or hyponatremia.  Do not use in dogs with known hypersensitivity to ACE inhibitors or spironolactone. The safety and effectiveness of concurrent therapy of CARDALIS™ with pimobendane has not been evaluated. The safety of CARDALIS™ has not been evaluated in pregnant, lactating, breeding, or growing dogs. CARDALIS™ administration should begin after pulmonary edema is stabilized. Regular monitoring of renal function and serum potassium levels is recommended. Common side effects from a field study include anorexia, vomiting, lethargy, diarrhea and renal insufficiency.